Will be starting CaAKG{Calcium Alpha-Ketoglutarate]
I am shamelessly copying a commercial product, in my view the commercial product is expensive for what is being sold.
My version/mix/set;
CaAKG - 1,000mg{2x 500mg capsule]
Calcium Oratate - 170mg of Calcium from 1,486mg of calcium orotate - 2X capsule
Dry Vitamin A - 7,500mcg {60% as Beta Carotene and 40% Retiny Palmitate] 1x capsule
1 set per day
Hi @Joseph , yes CaAKG is interesting, and I agree, given the price premium for the Rejuvant , I can see why people would be “making their own”.
I’ve seen conflicting research on CaAKG in terms of mTOR inhibition and activation (see two papers below) but I have not researched it in depth. Have you researched this issue - or anyone else here?
More details for those interested in CaAKG:
And a report by the Alzheimer’s Drug Discovery Foundation on CaAKG:
Alpha-ketoglutarate-Cognitive-Vitality-For-Researchers-2.pdf (283.3 KB)
Brian Kennedy spoke about this at the 2021 ARDD. The studies were ongoing then but he said the company had a lot of data from people like us that set baselines for DNA methylation and just started taking the product. And then tested every 6 months. He said that that that data was promising. I suspect that the company that makes Rejuvant would have thought that would suffice. But he went on to explain why.
He said that I think what we are seeing is that if you think you’re getting younger, then you are getting younger. And, the people who are spending money to buy the product are hopefully getting a benefit from AKG but the are also getting a benefit from thinking they were doing something to affect aging! These companies must love their paid scientific advisors!
Tried Calcium AKG a few months ago, for two months. Did not notice any changes. But my assessment is subjective. I did not measure any biomarkers. I used another brand, Maxx herbs, because of the lower price. So the fault may be in el cheapo me, not the supplement.
A scientific study, however, gave the following assessment:
In females, aKG treatment resulted in significant increases in median and maximal (90th percentile) lifespan (16.6% and 19.7%, respectively), while in males median and maximal lifespan were numerically greater, but not significant (9.6% and 12.8%, respectively). Independent of sex, aKG treatment decreased the proportion of life in which mice were frail, with reduction in frailty scores of 46% for females and 41% for males on the aKG diet.